Hemogenyx Pharmaceuticals plc

31 January 2020

Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has been advised that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), purchased 257,069 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.945p per share. Following this transaction, Mr Wright now has a total beneficial interest in 1,097,405 Ordinary Shares, representing approximately 0.28 per cent of the Company's issued share capital as enlarged by the placing announced on 30 January 2020.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	**Details of PDMR/person closely associated with them ("PCA")**	
a)	Name	Andrew Wright
b)	Position/status	Financial Controller and Company Secretary/PDMR (non-board)
c)	Initial notification/ amendment	Initial notification
2.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument	Ordinary shares of 1p of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24

b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>*GBP £0.01945*</td><td>*257,069*</td></tr></table>
d)	Aggregated information - Aggregated volume - Price	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>*GBP £4,999.99*</td><td>*257,069*</td></tr></table>
e)	Date of the transaction	*30 January 2020*
f)	Place of the transaction	*London Stock Exchange* *XLON*

Enquiries:

Hemogenyx Pharmaceuticals plc www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com

Sir Marc Feldmann, Chairman

SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey

US Media enquiries Tel: +1 (323) 646-3249

Lowell Goodman lowell@corbomitecomms.com